GL CHEMTEC Announces Completion of a New GMP Facility for Advanced Pharmaceutical Materials

Img
Biotechnology Technology Manufacturing Health General Health Pharmaceutical Other Science Research Other Manufacturing Nanotechnology Science

GL CHEMTEC Announces Completion of a New GMP Facility for Advanced Pharmaceutical Materials

Media Contact – Katy Bartow, Senior Director, katy@mezzaninegrowth.com, Mezzanine Growth

GL CHEMTEC, a leading North American-based CDMO providing advanced chemistry services to the pharmaceutical and biotech sectors, is pleased to announce the completion of our state-of-the-art Good Manufacturing Practice (GMP) Kilo lab facility. This strategic expansion strengthens our commitment to delivering high-quality materials to our valued customers across the pharmaceutical and life science sectors.

The new, fully operational Kilo scale GMP facility will serve increased customer demand for advanced materials suitable for use in human clinical trials. This investment enables GL CHEMTEC to bridge the gap between pre-clinical offerings and first-in-human, offering our clients a seamless pathway from concept to clinic and commercialization.

"Our new Kilo lab GMP facility represents a significant milestone in GL CHEMTEC’s growth strategy," said Dr. Gamil Alhakimi, CEO. "By enhancing our capabilities in material science and drug delivery, we can better serve our customers with faster development cycles, superior quality control, and more efficient scaling processes."

Key features of the new GMP facility:

  • Two state-of-the-art specialized rooms designed to meet ISO 8 particulate and microbiological specifications
  • Enhanced quality control systems
  • Significantly increased production capacity at the multi-Kilogram scale
  • A dedicated team of world-class Biomedical Polymer Science and Drug Delivery experts

The facility is now fully operational and accepting new projects. Current customers can contact their GL CHEMTEC representative for more information on how this new capability can benefit their existing and future projects. Prospective clients are invited to visit the GL CHEMTEC website to learn more.

"This investment is a further testament to GL CHEMTEC’s unwavering commitment to advancing drug development and delivery solutions," Dr. Alhakimi stated. "We are now better positioned to support our partners in navigating the complexities of scale-up and clinical trials, ultimately contributing to a healthier future."

About GL CHEMTEC

Over the last two decades, GL CHEMTEC has established itself as a leader in the life sciences sector, delivering sustainable, innovative solutions with unparalleled speed and passion. The company’s track record of success is rooted in an unwavering commitment to their customers and their unique ability to adapt to diverse needs through a flexible, collaborative approach. Located in North America, GL CHEMTEC provides a secure supply chain, enabling accelerated early-stage API development and the seamless transition of innovative drug delivery solutions from research and development to manufacturing.